Wright Brings Broad Healthcare and Diagnostics Expertise to Biotech’s Board;

Current CEO of Madison Industries Medical Division & Previous EVP of Clinical Diagnostics at Bio-Rad

Cleveland Diagnostics, Inc., a cancer biotechnology company, today announced the appointment of a new independent director, Dara Grantham Wright, to its Board of Directors. Wright’s extensive experience in life science research and clinical diagnostics will be an asset to Cleveland Diagnostics as it expands commercialization of its IsoPSA^® prostate cancer test, and brings new products to the market.

Wright is a growth-oriented leader with a demonstrated track record of building commercial success in the life sciences and clinical sectors with direct experience in both the Clinical Laboratory and In Vitro Diagnostics (IVD) environments. She’s held successively senior executive leadership positions at several leading organizations, including Bio-Rad, Thermo Fisher Scientific, and Becton Dickinson.

“I am honored to join the Board of Directors at Cleveland Diagnostics,” said Wright. “I look forward to supporting their mission of expanding access to leading-edge diagnostic tests to significantly enhance early cancer detection.”

Wright is joining a board currently comprising Noel Jee of Novo Holdings, Sameer Rohatgi of Lyfe Capital, Joe Rich of Cleveland Clinic, and Cleveland Diagnostics’ CEO Arnon Chait.

“I am very pleased to have Dara join our Board,” shared Arnon Chait, PhD, company president and CEO. “Dara’s extensive hands-on experience in scaling up both small and large companies in the diagnostics space will be incredibly valuable as Cleveland Diagnostics navigates commercializing our unique, highly accurate cancer tests – especially as we explore new therapeutic areas with our proprietary platform, IsoClear™. I am eager to have Dara contribute to our future and look forward to working closely with her.”

Wright’s appointment follows a growth equity financing earlier this year, through which Cleveland Diagnostics successfully secured $75M in financing to advance the development of its proprietary structure-focused early cancer detection testing platform, IsoClear. The company’s R&D team continues to actively explore the potential of IsoClear in other disease states to build a new class of clinical laboratory tests that help deepen clinical insights and reduce unnecessary, invasive procedures for patients.

For more information and company news, visit ClevelandDx.com

About Cleveland Diagnostics, Inc.

Cleveland Diagnostics is a breakthrough cancer biotechnology company that is changing the shape of cancer detection. The company has unlocked the diagnostic power of protein structure with its revolutionary IsoClear™ platform that enables novel diagnostics based on a single cancer-specific, protein structure-based assessment using easy to execute tests within the clinical lab setting. Learn more at ClevelandDx.com and IsoPSA.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240723788229/en/